nafamostat has been researched along with Crohn Disease in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Crohn Disease: A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagase, K | 1 |
| Sawada, K | 1 |
| Ohnishi, K | 1 |
| Egashira, A | 1 |
| Ohkusu, K | 1 |
| Shimoyama, T | 1 |
1 other study available for nafamostat and Crohn Disease
| Article | Year |
|---|---|
Complications of leukocytapheresis.
Topics: Adult; Anticoagulants; Benzamidines; Colitis, Ulcerative; Crohn Disease; Female; Guanidines; Heparin | 1998 |